PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35119129-14	2022	Plasma cholecystokinin was greater for cows infused with LCFA compared with CONT.	Cholecystokinin	7-22	LCFA	Bos taurus	57-61
3214705-1	1988	Cholecystokinin octapeptide (CCK-8) binding sites were examined in the caudal hindbrain of unilaterally nodosectomized and intact rats by in vitro autoradiography with 125I-CCK-8.	Cholecystokinin	29-32	cholecystokinin	Rattus norvegicus	0-15
34662392-6	2022	In the intestinal mucosa, GLP-1R staining was observed in intraepithelial lymphocytes, lamina propria lymphocytes, and enteroendocrine cells containing secretin, peptide YY, and somatostatin, but not cholecystokinin.	Cholecystokinin	200-215	glucagon-like peptide 1 receptor	Mus musculus	26-32
35154452-12	2022	In vitro experiments indicated that knocking down SEC61G considerably impaired the colony formation, cck-8, migration, and invasion, and induced apoptosis of the breast cancer cell lines.	Cholecystokinin	101-104	SEC61 translocon subunit gamma	Homo sapiens	50-56
35366980-3	2022	Repeat injection of cerulein, a cholecystokinin (CCK) analog, is widely used to experimentally induce acute and chronic pancreatitis in vivo.	Cholecystokinin	32-47	cholecystokinin	Mus musculus	49-52
2655616-2	1989	Stimulation of phospholipase C (PLC) by agonists such as cholecystokinin (CCK), carbachol (Cch) or GTP-gamma-S, a weakly hydrolysable GTP-analog, induced production of inositol-1,4,5-trisphosphate (IP3) by hydrolysis of its precursor phosphatidylinositol-4,5-bisphosphate (PIP2).	Cholecystokinin	57-72	cholecystokinin	Rattus norvegicus	74-77
3046973-6	1988	L 364718, at levels 10- to 100-fold greater than those necessary to attenuate CCK-8S-induced insulin secretion, had no adverse effect on the insulin secretory response of freshly isolated islets to 10 mM glucose alone, 5 mM D-glyceraldehyde, 15 mM alpha-ketoisocaproate, or 50 ng/ml gastric inhibitory polypeptide.	Cholecystokinin	78-81	insulin	Homo sapiens	93-100
2902657-5	1988	We report here that VIP is a potent inhibitor of serum-induced DNA synthesis in cultured smooth muscle cells (SMC), whereas no growth-inhibition was seen in SMC exposed to neurokinin A, calcitonin-gene related peptide, neuropeptide Y, somatostatin, or cholecystokinin.	Cholecystokinin	252-267	vasoactive intestinal peptide	Homo sapiens	20-23
2458391-1	1988	The distribution of neurotensin immunoreactivity in the basal ganglia of the adult rat was evaluated by studying alternate serial vibratome sections that were exposed to antiserum against neurotensin, substance P, or cholecystokinin.	Cholecystokinin	217-232	neurotensin	Rattus norvegicus	20-31
7044859-3	1982	In control patients, pancreozymin (CCK) injection led to increases in specific activities of trypsin and chymotrypsin and a decrease in EK but did not change the total EK activities.	Cholecystokinin	21-33	cholecystokinin	Homo sapiens	35-38
3028057-3	1986	The purpose of the present study was to investigate the effects of norepinephrine, isoproterenol, methacholine, and cholecystokinin on the simultaneous release of kallikrein and tonin from the rat submandibular gland.	Cholecystokinin	116-131	kallikrein 1-related peptidase C2	Rattus norvegicus	178-183
2578456-8	1985	In the presence of carbamylcholine or cholecystokinin stimulation, the times required for 40% discharge of labeled chymotrypsinogen 2, trypsinogen, amylase, and procarboxypeptidase B were 98, 102, 148, and 180 min, respectively.	Cholecystokinin	38-53	trypsinogen	Cavia porcellus	120-131
6884978-0	1983	Effect of CCK-33 on prolactin and apomorphine-induced growth hormone secretion in man.	Cholecystokinin	10-16	prolactin	Homo sapiens	20-29
6884978-0	1983	Effect of CCK-33 on prolactin and apomorphine-induced growth hormone secretion in man.	Cholecystokinin	10-16	growth hormone 1	Homo sapiens	54-68
6304053-2	1983	In dispersed acini from guinea pig pancreas, cholecystokinin-27-32-amide (CCK-27-32-NH2) did not alter amylase secretion but was able to antagonize the stimulation caused by cholecystokinin-related agonists.	Cholecystokinin	45-60	cholecystokinin	Cavia porcellus	74-77
6897074-6	1982	When the stimulus for gallbladder emptying is changed from whole-meal ingestion to cholecystokinin injection, the absorbed dose to the gallbladder increases to approximately 1 rad/mCi; if no gallbladder emptying is assumed, its absorbed dose increases to approximately 1.9 rad/mCi.	Cholecystokinin	83-98	multiciliate differentiation and DNA synthesis associated cell cycle protein	Mus musculus	180-183
6897074-6	1982	When the stimulus for gallbladder emptying is changed from whole-meal ingestion to cholecystokinin injection, the absorbed dose to the gallbladder increases to approximately 1 rad/mCi; if no gallbladder emptying is assumed, its absorbed dose increases to approximately 1.9 rad/mCi.	Cholecystokinin	83-98	multiciliate differentiation and DNA synthesis associated cell cycle protein	Mus musculus	277-280
3807051-1	1986	Two beta-carbolines, methyl beta-carboline-3-carboxylate (beta-CCM) and ethyl beta-carboline-3-carboxylate (beta-CCE), caused the parallel shift of the dose-response curve for cholecystokinin (CCK) in isolated guinea-pig gallbladder muscle.	Cholecystokinin	176-191	cholecystokinin	Cavia porcellus	193-196
3765831-1	1986	In experiments on 15 freely moving rabbits cholecystokinin octapeptide sulfate (CCK-8-S) in a dose of 10 ng considerably suppressed alimentary behaviour of the animals elicited by electrical stimulation of the lateral hypothalamus.	Cholecystokinin	43-58	cholecystokinin	Oryctolagus cuniculus	80-83
3529010-0	1986	[Effect of pancreozymin on insulin secretion in experimental chronic pancreatitis].	Cholecystokinin	11-23	insulin	Homo sapiens	27-34
6281507-9	1982	These results indicate that CCK-8 has a sedative action and antagonizes the behavioral excitation caused by TRH and methamphetamine, but that the effects of CCK-8-NS and caerulein were rather the opposite of those of CCK-8.	Cholecystokinin	28-31	thyrotropin releasing hormone	Rattus norvegicus	108-111
7270539-12	1981	Pancreozymin administration (2 U./kg) produced a significant decrease (P less than 0.01) in Ig-A concentration (11.2 +/- 0.8 mg./gm.	Cholecystokinin	0-12	immunoglobulin heavy variable 4-38-2-like	Homo sapiens	92-96
6166201-4	1981	The ability of butyryl cyclic GMP to reverse cholecystokinin-induced residual stimulation is itself fully reversible, and the nucleotide-induced reversal is accompanied by restoration of full responsiveness to cholecystokinin.	Cholecystokinin	45-60	5'-nucleotidase, cytosolic II	Homo sapiens	30-33
436775-2	1979	[D-Trp8-D-Cys14]somatostatin, at a concentration of 200 ng/ml, blocked the response of somatostatin-like immunoreactivity (SLI) to cholecystokinin and arginine.	Cholecystokinin	131-146	somatostatin	Canis lupus familiaris	16-28
6245588-2	1980	Each enterocyte possessed approximately 60,000 binding sites and binding of the tracer to these sites could be inhibited by VIP [concentration for half-maximal effect (Kd), 12 nM] and by secretin (Kd greater than 1 micro M), but not by glucagon, gastrin, cholecystokinin, calcitonin, bombesin, litorin, physalaemin, substance P, eledoisin, serotonin, carbamylcholine, or histamine.	Cholecystokinin	255-270	VIP peptides	Cavia porcellus	124-127
6156397-0	1980	Butyryl derivatives of cyclic GMP interfere with the biological and the immunological properties of the pancreozymin-gastrin family of peptides.	Cholecystokinin	104-116	5'-nucleotidase, cytosolic II	Homo sapiens	30-33
436775-2	1979	[D-Trp8-D-Cys14]somatostatin, at a concentration of 200 ng/ml, blocked the response of somatostatin-like immunoreactivity (SLI) to cholecystokinin and arginine.	Cholecystokinin	131-146	somatostatin	Canis lupus familiaris	87-99
198531-8	1977	The responses to CCK-OP or carbamylcholine were potentiated by secretin, VIP or dibutyryl cyclic AMP.	Cholecystokinin	17-20	vasoactive intestinal peptide	Homo sapiens	73-76
705248-2	1978	Secretin and glucagon in concentrations that did not significantly alter spontaneous activity significantly reduced antral responses to cholecystokinin, but had no depressive effect on the fundal responses.	Cholecystokinin	136-151	secretin	Cavia porcellus	0-8
173397-10	1976	The Ca2+ antagonist D600 blocks the stimulatory effects of both carbamylcholine and pancreozymin only partially.	Cholecystokinin	84-96	carbonic anhydrase 2	Rattus norvegicus	4-7
168355-5	1975	The effect of both acetylcholine (ACh) and pancreozymin (CCK-Pz) on the pancreas in vivo as well as in vitro was to reduce both the acinar cell membrane potential and the input resistance narkedly.	Cholecystokinin	43-55	cholecystokinin	Rattus norvegicus	57-60
5774112-3	1969	In response to prolonged intravenous infusion of arginine with pancreozymin there was a maintained rise in immunoreactive insulin and glucagon-like immunoreactivity in the blood.	Cholecystokinin	63-75	insulin	Homo sapiens	122-129
4594610-0	1974	Effect of 2-deoxy-D-glucose and mannoheptulose on the insulin response to pancreozymin in rabbits.	Cholecystokinin	74-86	insulin	Oryctolagus cuniculus	54-61
4790025-0	1973	[Excretory pancreatic function in the rat: inhibition by high doses of CCK pancreozymin and anesthesia].	Cholecystokinin	75-87	cholecystokinin	Rattus norvegicus	71-74
5774112-6	1969	Enteric infusion of arginine, presumed to cause release of endogenous pancreozymin, led to a rise in serum immunoreactive insulin not attributable to effects of circulating glucose and amino acids.	Cholecystokinin	70-82	insulin	Homo sapiens	122-129
5676526-3	1968	Further augmentation of both insulin and glucagon secretion was achieved during hyperaminoacidemia by infusing pancreozymin.	Cholecystokinin	111-123	insulin	Canis lupus familiaris	29-36
32940875-8	2021	Importantly, TUNEL and CCK-8 assays both demonstrated that treatment with p53 antagonist pifithrin-alpha (PFT-alpha) markedly attenuated TPEN-induced OEC apoptosis.	Cholecystokinin	23-26	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	74-77
34035343-0	2021	Cionin, a vertebrate cholecystokinin/gastrin homolog, induces ovulation in the ascidian Ciona intestinalis type A.	Cholecystokinin	21-36	cionin	Ciona intestinalis	0-6
34035343-1	2021	Cionin is a homolog of vertebrate cholecystokinin/gastrin that has been identified in the ascidian Ciona intestinalis type A.	Cholecystokinin	34-49	cionin	Ciona intestinalis	0-6
33303271-12	2021	CONCLUSION: Our data indicate that beta-1 blocker reduces systemic and local inflammatory responses and preserves intestinal barrier function after open abdominal surgery through a mechanism that depends on cholecystokinin receptors.	Cholecystokinin	207-222	UDP glucuronosyltransferase family 1 member A6	Rattus norvegicus	35-41
33152231-10	2021	In addition, the CCK-8, MTT and EdU results demonstrated that miR-185 promotes IPEC-J2 cells proliferation by targeting CDC42.	Cholecystokinin	17-20	microRNA 185	Sus scrofa	62-69
33152231-10	2021	In addition, the CCK-8, MTT and EdU results demonstrated that miR-185 promotes IPEC-J2 cells proliferation by targeting CDC42.	Cholecystokinin	17-20	cell division control protein 42 homolog	Sus scrofa	120-125
33041265-7	2021	In the CCK-8, wound healing assays and Transwell  experiments, the additive effects on cell proliferation and migration were observed in the presence of exogenous MOF and GEM.	Cholecystokinin	7-10	lysine acetyltransferase 8	Homo sapiens	163-166
33754583-11	2021	Moreover, flow cytometry-Annexin V/PI staining and CCK-8 assay results revealed that in EPO-treated cells, knocking down PTPN1 and PTPN11 significantly reversed the protective effect of EPO against high glucose-induced retinal ganglion cell apoptosis (P<0.05).	Cholecystokinin	51-54	erythropoietin	Rattus norvegicus	88-91
33754583-11	2021	Moreover, flow cytometry-Annexin V/PI staining and CCK-8 assay results revealed that in EPO-treated cells, knocking down PTPN1 and PTPN11 significantly reversed the protective effect of EPO against high glucose-induced retinal ganglion cell apoptosis (P<0.05).	Cholecystokinin	51-54	protein tyrosine phosphatase, non-receptor type 1	Rattus norvegicus	121-126
33754583-11	2021	Moreover, flow cytometry-Annexin V/PI staining and CCK-8 assay results revealed that in EPO-treated cells, knocking down PTPN1 and PTPN11 significantly reversed the protective effect of EPO against high glucose-induced retinal ganglion cell apoptosis (P<0.05).	Cholecystokinin	51-54	erythropoietin	Rattus norvegicus	186-189
33103448-7	2021	The CRHP diet increased postprandial glucagon net AUC by 235% (P < 0.001), subjective satiety by 18% (P = 0.03), delayed gastric emptying by 15 min (P < 0.001), decreased gastric inhibitory polypeptide net AUC by 29% (P < 0.001), but had no significant effect on glucagon-like-peptide-1, total peptide YY, and cholecystokinin responses.	Cholecystokinin	310-325	cysteine rich protein 1	Homo sapiens	4-8
33299180-4	2021	Here we demonstrate that when mice engage in spatial exploration of novel environments, perisomatic inhibition of Fos-activated hippocampal CA1 pyramidal neurons by parvalbumin-expressing interneurons is enhanced, whereas perisomatic inhibition by cholecystokinin-expressing interneurons is weakened.	Cholecystokinin	248-263	FBJ osteosarcoma oncogene	Mus musculus	114-117
33952826-8	2021	P-gp functional changes were blocked by YM022, an inhibitor of cholecystokinin (CCK) receptor.	Cholecystokinin	63-78	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
32920089-3	2020	Cholecystokinin (CCK) acts on the central nervous system by elevating thermogenesis and the activity of anorectic neurons, modulating overall energy balance.	Cholecystokinin	0-15	cholecystokinin	Rattus norvegicus	17-20
33264079-3	2021	Based on CCK-8 and Hoechst staining results, silencing of TFAP2A could enhance the viability of OGD-treated PC12 cells and decrease the apoptotic rate of cells.	Cholecystokinin	9-12	transcription factor AP-2 alpha	Rattus norvegicus	58-64
33115780-3	2021	Blood levels of the gastrointestinal peptide cholecystokinin (CCK) are increased in humans and mice consuming a high-fat diet.	Cholecystokinin	45-60	cholecystokinin	Homo sapiens	62-65
33721432-3	2021	The cell proliferative ability after overexpression of CLK2 was determined via cell counting kit-8 (CCK-8) and 5-Ethynyl-2"- deoxyuridine (EdU) assays.	Cholecystokinin	100-103	CDC like kinase 2	Homo sapiens	55-59
33151898-1	2021	Cholecystokinin (CCK) is secreted from enteroendocrine I cells in response to fat, carbohydrate, and protein ingestion.	Cholecystokinin	0-15	cholecystokinin	Mus musculus	17-20
32482410-1	2020	PURPOSE: Cholecystokinin stimulated HIDA (CCK-HIDA) has been used to identify patients with biliary dyskinesia and select patients likely to benefit from cholecystectomy.	Cholecystokinin	9-24	cholecystokinin	Homo sapiens	42-45
32661781-0	2020	The Combination of Cholecystokinin and Stress Amplifies an Inhibition of Appetite, Gastric Emptying, and an Increase in c-Fos Expression in Neurons of the Hypothalamus and the Medulla Oblongata.	Cholecystokinin	19-34	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	120-125
32628919-0	2020	Cholecystokinin and bombesin activate neuronatin neurons in the nucleus of the solitary tract.	Cholecystokinin	0-15	neuronatin	Rattus norvegicus	38-48
32877641-3	2020	Here we report the role of endogenous neuropeptide cholecystokinin (CCK), released from dentate CCK interneurons, in regulating neurogenic niche cells and NSCs.	Cholecystokinin	51-66	cholecystokinin	Homo sapiens	68-71
32877641-3	2020	Here we report the role of endogenous neuropeptide cholecystokinin (CCK), released from dentate CCK interneurons, in regulating neurogenic niche cells and NSCs.	Cholecystokinin	51-66	cholecystokinin	Homo sapiens	96-99
32661781-1	2020	Cholecystokinin (CCK) had been the first gastrointestinal hormone known to exert anorexic effects.	Cholecystokinin	0-15	cholecystokinin	Rattus norvegicus	17-20
32605937-4	2020	Here we combined optogenetics with electrophysiology to characterize the synaptic transmission from a subpopulation of TCs, which exclusively express the neuropeptide cholecystokinin (CCK), to two groups of spatially segregated GABAergic interneurons - granule cells (GCs) and glomerular interneurons in mice of both sexes with four major findings.	Cholecystokinin	167-182	cholecystokinin	Mus musculus	184-187
32723474-0	2020	The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling.	Cholecystokinin	61-76	growth differentiation factor 15	Mus musculus	13-18
32407928-8	2020	Interestingly, cholecystokinin is only transported into the liver by OATP1B3.	Cholecystokinin	15-30	solute carrier organic anion transporter family member 1B3	Homo sapiens	69-76
32629699-6	2020	METHODS: The model of ITGB1 inhibition and overexpression was firstly constructed in LS174T cells, and the viability of cells in each group was detected using CCK-8 assay.	Cholecystokinin	159-162	integrin subunit beta 1	Homo sapiens	22-27
32073876-1	2020	Cholecystokinin (CCK) is a gut-derived peptide that potently promotes satiety and facilitates gastric function in part by activating G protein-coupled CCK1 receptors on primary vagal afferent neurons.	Cholecystokinin	0-15	cholecystokinin	Homo sapiens	17-20
31821012-14	2020	Cholecystokinin may play a role in the effect of apelin through sensory neurons.	Cholecystokinin	0-15	apelin	Homo sapiens	49-55
32292065-0	2020	Ghrelin signaling contributes to fasting-induced attenuation of hindbrain neural activation and hypophagic responses to systemic cholecystokinin in rats.	Cholecystokinin	129-144	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
32073876-1	2020	Cholecystokinin (CCK) is a gut-derived peptide that potently promotes satiety and facilitates gastric function in part by activating G protein-coupled CCK1 receptors on primary vagal afferent neurons.	Cholecystokinin	0-15	C-C motif chemokine ligand 28	Homo sapiens	151-155
31815784-6	2020	RECENT FINDINGS: Recent approaches, in animal models or in humans, use synthetic GLP-1 receptor agonists, a centrally administered antibody neutralizing GIP receptor, curcumin, compound being active on nesfatin, resveratrol (antiinflammatory agent), and Ginseg, both of them acting on nesfatin, a cholecystokinin receptor analogue, and finally coffee functioning on YY peptide.	Cholecystokinin	297-312	glucagon like peptide 1 receptor	Homo sapiens	81-95
31604888-2	2020	It can also provide the opportunity to quantify an individual"s responsiveness to the physiological stimulant of gallbladder contraction, cholecystokinin (CCK), which is a major regulator of appetite and post-prandial satiety.	Cholecystokinin	138-153	cholecystokinin	Homo sapiens	155-158
31604888-3	2020	Methods: In the current work, we utilize cholecystokinin-cholescintigraphy to quantify the kinetics of gallbladder emptying, including average and peak rates, in response to a standard CCK infusion.	Cholecystokinin	41-56	cholecystokinin	Homo sapiens	185-188
32081451-1	2020	This paper describes the early history of Gastric Inhibitory Polypeptide, better referred to simply as GIP, from its isolation by purification from a crude preparation of CCK-PZ (cholecystokinin/pancreozymin) to its recognition as a key play in the pathogenesis of obesity and other metabolic disorders far removed from the enterogastrone properties by which it was originally identified.	Cholecystokinin	171-177	gastric inhibitory polypeptide	Homo sapiens	103-106
32081451-1	2020	This paper describes the early history of Gastric Inhibitory Polypeptide, better referred to simply as GIP, from its isolation by purification from a crude preparation of CCK-PZ (cholecystokinin/pancreozymin) to its recognition as a key play in the pathogenesis of obesity and other metabolic disorders far removed from the enterogastrone properties by which it was originally identified.	Cholecystokinin	179-194	gastric inhibitory polypeptide	Homo sapiens	103-106
32081451-1	2020	This paper describes the early history of Gastric Inhibitory Polypeptide, better referred to simply as GIP, from its isolation by purification from a crude preparation of CCK-PZ (cholecystokinin/pancreozymin) to its recognition as a key play in the pathogenesis of obesity and other metabolic disorders far removed from the enterogastrone properties by which it was originally identified.	Cholecystokinin	195-207	gastric inhibitory polypeptide	Homo sapiens	103-106
30998649-3	2020	Cholecystokinin (CCK) is a peptide synthesized by several cell types, whose immunomodulatory activity has been reported in experimental models of inflammation.	Cholecystokinin	0-15	cholecystokinin	Rattus norvegicus	17-20
30149298-1	2018	Endogenous cholecystokinin tetrapeptide (CCK-4, Trp-Met-Asp-Phe-NH2) is a fragment derived from a larger peptide hormone, cholecystokinin (or gastrin).	Cholecystokinin	11-26	protein tyrosine kinase 7 (inactive)	Homo sapiens	41-46
31081147-4	2019	Classical pathway analysis revealed a total of 89 signal transduction pathways with upregulated gene set enrichment, including lipopolysaccharide/interleukin (IL)-1-mediated inhibition of retinoid X receptor (RXR) function, agrin interactions at neuromuscular junctions, cholecystokinin/gastrin-mediated signaling, toll-like receptor signaling, and IL-6 signaling.	Cholecystokinin	271-286	retinoid X receptor alpha	Homo sapiens	188-207
31302653-4	2019	AngII-induced cell growth were detected by CCK-8.	Cholecystokinin	43-46	angiotensinogen	Homo sapiens	0-5
31098764-6	2019	Many genes that were enriched in other local VIP+ cell types, including the interneuron-selective interneurons and the cholecystokinin-coexpressing basket cells, were detected in VIP+ subiculum-projecting cells.	Cholecystokinin	119-134	vasoactive intestinal polypeptide	Mus musculus	45-48
31098764-6	2019	Many genes that were enriched in other local VIP+ cell types, including the interneuron-selective interneurons and the cholecystokinin-coexpressing basket cells, were detected in VIP+ subiculum-projecting cells.	Cholecystokinin	119-134	vasoactive intestinal polypeptide	Mus musculus	179-182
31215470-1	2019	BACKGROUND: Cholecystokinin (CCK) is implicated in the regulation of nociceptive sensitivity of primary afferent neurons.	Cholecystokinin	12-27	cholecystokinin	Mus musculus	29-32
31215470-4	2019	RESULTS: CCK-8 reversibly and concentration-dependently decreased A-type K+ channel (IA) in small-sized dorsal root ganglion (DRG) neurons through the activation of CCK type B receptor (CCK-BR), while the sustained delayed rectifier K+ current was unaffected.	Cholecystokinin	9-13	cholecystokinin B receptor	Mus musculus	165-184
31215470-4	2019	RESULTS: CCK-8 reversibly and concentration-dependently decreased A-type K+ channel (IA) in small-sized dorsal root ganglion (DRG) neurons through the activation of CCK type B receptor (CCK-BR), while the sustained delayed rectifier K+ current was unaffected.	Cholecystokinin	9-13	cholecystokinin B receptor	Mus musculus	186-192
30739077-1	2019	Cholecystokinin (CCK) is a satiety hormone that is highly expressed in brain regions like the hippocampus.	Cholecystokinin	0-15	cholecystokinin	Homo sapiens	17-20
30149298-1	2018	Endogenous cholecystokinin tetrapeptide (CCK-4, Trp-Met-Asp-Phe-NH2) is a fragment derived from a larger peptide hormone, cholecystokinin (or gastrin).	Cholecystokinin	11-26	gastrin	Homo sapiens	142-149
29360461-11	2018	RESULTS: Human pancreatic tissues and dispersed pancreatic acini from control mice exposed to CCK-8 or ethanol plus CCK-8 were depleted of STX2.	Cholecystokinin	94-97	syntaxin 2	Mus musculus	139-143
28669533-4	2018	Multiple factors were studied as related to cholescintigraphy scans with cholecystokinin administration (HIDA with CCK).	Cholecystokinin	73-88	cholecystokinin	Homo sapiens	115-118
28351548-6	2017	Based on our previous findings, we also found significant correlations between GAD67, GAT1 and parvalbumin while GAD67, GAD65 and GAT1 were positively correlated with cholecystokinin in the PRL of METH sensitized rats.	Cholecystokinin	167-182	glutamate decarboxylase 1	Rattus norvegicus	113-118
28938439-7	2017	Interventions: Four experimental study days in randomized order with administration of either 1500 mg metformin or placebo in combination with intravenous infusion of cholecystokinin (0.4 pmol x kg-1 x min-1) or saline.	Cholecystokinin	167-182	CD59 molecule (CD59 blood group)	Homo sapiens	202-207
28938439-12	2017	Conclusions: Metformin elicited an enhancement of the GLP-1 response to cholecystokinin-induced gallbladder emptying in patients with type 2 diabetes, whereas no derived effects on insulin or glucagon secretion were evident in this acute setting.	Cholecystokinin	72-87	glucagon	Homo sapiens	54-59
28351548-6	2017	Based on our previous findings, we also found significant correlations between GAD67, GAT1 and parvalbumin while GAD67, GAD65 and GAT1 were positively correlated with cholecystokinin in the PRL of METH sensitized rats.	Cholecystokinin	167-182	glutamate decarboxylase 2	Rattus norvegicus	120-125
28351548-6	2017	Based on our previous findings, we also found significant correlations between GAD67, GAT1 and parvalbumin while GAD67, GAD65 and GAT1 were positively correlated with cholecystokinin in the PRL of METH sensitized rats.	Cholecystokinin	167-182	solute carrier family 6 member 1	Rattus norvegicus	130-134
18400903-2	2008	Here, we used genetic fate mapping to show that Tlx3(+) spinal cord neurons and their derivatives represent a heterogeneous population of neurons, marked by partially overlapping expression of a set of neuropeptide genes, including those encoding the anti-opioid peptide cholecystokinin, pronociceptive Substance P (SP), Neurokinin B, and a late wave of somatostatin.	Cholecystokinin	271-286	T cell leukemia homeobox 3	Homo sapiens	48-52
23959730-2	2013	Additionally, we assessed whether the pronociceptive actions induced by intrathecally administered dynorphin A, cholecystokinin or prostaglandin F(2alpha) are mediated by the spinal TRPA1 channel.	Cholecystokinin	112-127	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	182-187
22983899-1	2012	C-terminally amidated gastrins act at cholecystokinin-2 receptors (CCK2R), which are normally expressed by gastric parietal and enterochromaffin-like (ECL) cells and smooth muscle; there is also extensive expression in the CNS where the main endogenous ligand is cholecystokinin.	Cholecystokinin	38-53	cholecystokinin B receptor	Homo sapiens	67-72
19445970-7	2009	Respective addition of cholecystokinin octapeptide and somatostatin with increasing concentrations caused rapid, sustained, concentration-dependent increase and decrease in muscle contraction of gastric antral strips, and cholecystokinin octapeptide that increased the contractile response could be blocked by respective administration of nifedipine and somatostatin significantly.	Cholecystokinin	23-38	somatostatin	Rattus norvegicus	354-366
27565679-8	2016	In conclusion, our study demonstrated a protective effect of CCK-8 on METH-induced neurotoxicity in vitro and suggested that a possible mechanism of this action was dependent on the activation of the CCK2 receptor to reduce the neurotoxicity and oxidative stress induced by METH stimulation.	Cholecystokinin	61-64	cholecystokinin B receptor	Rattus norvegicus	200-213
23179899-1	2013	YF476 differs from the proton pump inhibitor (PPI) esomeprazole in mode of action by antagonizing the type 2 receptor of cholecystokinin/gastrin (CCK-2R).	Cholecystokinin	121-136	cholecystokinin B receptor	Homo sapiens	146-152
20542702-2	2010	To our knowledge this is the first CCK4-based radioligand that presents a high affinity for the CCK2R, a high and specific tumor uptake, a low renal accumulation and a very good visualization of tumors in vivo compared with an internal control, 111Indium-trans-cyclohexyldiethylenetriaminepenta-acetic acid-cholecystokinin octapeptide (111In-CHX-A""-DTPA-CCK8).	Cholecystokinin	307-322	protein tyrosine kinase 7 (inactive)	Homo sapiens	35-39
20542702-2	2010	To our knowledge this is the first CCK4-based radioligand that presents a high affinity for the CCK2R, a high and specific tumor uptake, a low renal accumulation and a very good visualization of tumors in vivo compared with an internal control, 111Indium-trans-cyclohexyldiethylenetriaminepenta-acetic acid-cholecystokinin octapeptide (111In-CHX-A""-DTPA-CCK8).	Cholecystokinin	307-322	cholecystokinin B receptor	Homo sapiens	96-101
17324928-0	2007	Alcohol/cholecystokinin-evoked pancreatic acinar basolateral exocytosis is mediated by protein kinase C alpha phosphorylation of Munc18c.	Cholecystokinin	8-23	protein kinase C alpha	Homo sapiens	87-109
20641933-0	2004	(99m)Tc-Nicotinic acid/tricine/hydrazinonicotinamide-nonsulfated cholecystokinin-8 (99m)Tc-Nicotinic acid/tricine/hydrazinonicotinamide-nonsulfated cholecystokinin-8 ((99m)Tc-NA/tricine/HYNIC-nsCCK-8) is a radiolabeled peptide developed for single-photon emission computed tomography (SPECT) imaging of tumors that express the gastrin/cholecystokinin-2 (CCK-2) receptor (1).	Cholecystokinin	65-80	gastrin	Homo sapiens	327-334
20641933-0	2004	(99m)Tc-Nicotinic acid/tricine/hydrazinonicotinamide-nonsulfated cholecystokinin-8 (99m)Tc-Nicotinic acid/tricine/hydrazinonicotinamide-nonsulfated cholecystokinin-8 ((99m)Tc-NA/tricine/HYNIC-nsCCK-8) is a radiolabeled peptide developed for single-photon emission computed tomography (SPECT) imaging of tumors that express the gastrin/cholecystokinin-2 (CCK-2) receptor (1).	Cholecystokinin	65-80	cholecystokinin B receptor	Homo sapiens	354-369
17324928-0	2007	Alcohol/cholecystokinin-evoked pancreatic acinar basolateral exocytosis is mediated by protein kinase C alpha phosphorylation of Munc18c.	Cholecystokinin	8-23	syntaxin binding protein 3	Homo sapiens	129-136
15830228-1	2005	RATIONALE: Evidence suggests that gamma-aminobutyric acid (GABA) and cholecystokinin (CCK) have opposite roles in the regulation of anxiety.	Cholecystokinin	69-84	cholecystokinin	Mus musculus	86-89
17625947-3	2007	Recently, we demonstrated that NADPH oxidase subunits Nox1, p27phox, p47phox, and p67phox are constitutively expressed in pancreatic acinar cells, which are activated by cerulein, a cholecystokinin analogue.	Cholecystokinin	182-197	NADPH oxidase 1	Rattus norvegicus	54-58
17625947-3	2007	Recently, we demonstrated that NADPH oxidase subunits Nox1, p27phox, p47phox, and p67phox are constitutively expressed in pancreatic acinar cells, which are activated by cerulein, a cholecystokinin analogue.	Cholecystokinin	182-197	neutrophil cytosolic factor 1	Rattus norvegicus	69-76
12777967-1	2003	Cholecystokinin modulates the release of dopamine and dopamine-related behaviours in the mesolimbic pathway, where cholecystokinin and dopamine coexist in dopaminergic neurones.	Cholecystokinin	0-15	cholecystokinin	Homo sapiens	115-130
15765402-9	2005	RESULTS: Muscle cells from patients with chronic constipation exhibited impaired contraction in response to receptor-G-protein-dependent agonists (cholecystokinin [CCK], acetylcholine) and in response to the direct G-protein activator guanosine 5"-O-(3-thiophosphate).	Cholecystokinin	147-162	cholecystokinin	Homo sapiens	164-167
16596773-8	2005	Recent studies have demonstrated that endocannabinoids can function as retrograde messengers, modulating the release of different neurotransmitters, including opioids, gamma-aminobutyric acid (GABA), and cholecystokinin (CCK), which could explain some of the responses observed after the stimulation of the CB1 cannabinoid receptor.	Cholecystokinin	204-219	cholecystokinin	Mus musculus	221-224
15665139-1	2005	CCK-8 (L-aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartyl-L-phenylalaninamide hydrogen sulfate ester), a derivative of the gastrointestinal peptide hormone cholecystokinin, is specifically taken up into human hepatocytes by the organic anion transporter OATP1B3 (OATP8).	Cholecystokinin	0-3	cholecystokinin	Homo sapiens	180-195
15665139-1	2005	CCK-8 (L-aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartyl-L-phenylalaninamide hydrogen sulfate ester), a derivative of the gastrointestinal peptide hormone cholecystokinin, is specifically taken up into human hepatocytes by the organic anion transporter OATP1B3 (OATP8).	Cholecystokinin	0-3	solute carrier organic anion transporter family member 1B3	Homo sapiens	278-285
15665139-1	2005	CCK-8 (L-aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartyl-L-phenylalaninamide hydrogen sulfate ester), a derivative of the gastrointestinal peptide hormone cholecystokinin, is specifically taken up into human hepatocytes by the organic anion transporter OATP1B3 (OATP8).	Cholecystokinin	0-3	solute carrier organic anion transporter family member 1B3	Homo sapiens	287-292
11316737-1	2001	Inositol 1,4,5-trisphosphate receptor (IP3R) protein levels in isolated rat pancreatic islets were investigated in response to carbachol (CCh) and sulfated cholecystokinin 26-33 amide stimulation.	Cholecystokinin	156-171	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	39-43
12038963-0	2002	Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.	Cholecystokinin	25-41	tripeptidyl peptidase I	Mus musculus	86-109
12505692-3	2002	CB1 cannabinoid receptors, so far the only cloned cannabinoid receptor type in the CNS, are selectively expressed on the axon terminals of a subset of GABAergic inhibitory interneurons containing the neuropeptide cholecystokinin.	Cholecystokinin	213-228	cannabinoid receptor 1	Homo sapiens	0-3
11303046-1	2001	Dynorphin A(1-17) given intrathecally releases spinal cholecystokinin to produce an antianalgesic action against spinal morphine in the tail-flick test in CD-1 mice.	Cholecystokinin	54-69	prodynorphin	Mus musculus	0-16
11282117-7	2001	Cholecystokinin octapeptide (CCK-8) dose dependently reduced the antinociceptive effects of endomorphin-1 and endomorphin-2 in non-diabetic mice.	Cholecystokinin	29-32	cholecystokinin	Mus musculus	0-15
11303046-4	2001	A small dose of LE intrathecally produced antianalgesia that like that from dynorphin A(1-17) and cholecystokinin was eliminated by naltriben but not 7-benzylidenenaltrexone (delta(2)- and delta(1)-opioid receptor antagonist, respectively).	Cholecystokinin	98-113	prodynorphin	Mus musculus	16-18
9727040-0	1998	A role for the p38 mitogen-activated protein kinase/Hsp 27 pathway in cholecystokinin-induced changes in the actin cytoskeleton in rat pancreatic acini.	Cholecystokinin	70-85	mitogen activated protein kinase 14	Rattus norvegicus	15-51
10998107-2	2000	Due to a greater sensitivity of this antibody, a large proportion of boutons in the dendritic layers displaying symmetrical (GABAergic) synapses were also strongly immunoreactive for CB1 receptors, as were axon terminals of perisomatic inhibitory cells containing cholecystokinin.	Cholecystokinin	264-279	cannabinoid receptor 1 (brain)	Mus musculus	183-186
10320330-1	1999	In investigating the agonist binding site of the human brain cholecystokininB receptor (CCKBR), we employed the direct protein chemical approach using a photoreactive tritiated analogue of sulfated cholecystokinin octapeptide, which contains the p-benzoylbenzoyl moiety at the N-terminus, followed by purification of the affinity-labeled receptor to homogeneity.	Cholecystokinin	61-76	cholecystokinin B receptor	Homo sapiens	88-93
11078394-2	2000	Endothelin-1 (ET-1; 0.1-100.0 nM) caused graded tonic contractions with a CK50 (concentration causing response equivalent to 50% of KCl 80 mM) of 3.4 nM and EH (response to highest concentration) of 186 +/- 22, being 40-fold less potent than cholecystokinin-8 (CCK-8), 103-fold more potent than carbachol, but equipotent to ET-3, sarafotoxin S6c (S6c) and IRL 1620.	Cholecystokinin	261-264	endothelin-1	Oryctolagus cuniculus	0-12
10668930-3	1999	Cholecystokinin (CCK) modulates the release of dopamine in the mesolimbic pathway and affects dopamine-related behavior.	Cholecystokinin	0-15	cholecystokinin	Homo sapiens	17-20
9727040-0	1998	A role for the p38 mitogen-activated protein kinase/Hsp 27 pathway in cholecystokinin-induced changes in the actin cytoskeleton in rat pancreatic acini.	Cholecystokinin	70-85	heat shock protein family B (small) member 1	Rattus norvegicus	52-58
8877029-5	1996	In groups of healthy subjects (n = 6 each) stimulation of pancreatic polypeptide was assessed in five different tests: (i) insulin-hypoglycaemia; (ii) modified sham feeding; (iii) intravenous infusion of the cholecystokinin analogue ceruletide; (iv) injection of corticotropin releasing hormone; (v) infusion of the muscarinic acetylcholine agonist bethanechol.	Cholecystokinin	208-223	pancreatic polypeptide	Homo sapiens	58-80
10461364-5	1998	In contrast, the benzodiazepine-derived CCK-BR ligand, YM022, acted as a "true" high-affinity antagonist of cholecystokinin-induced inositol phosphate formation (pA2 = 9.69).	Cholecystokinin	108-123	cholecystokinin B receptor	Homo sapiens	40-46
9871461-6	1998	Dopamine (DA) and cholecystokinin (CCK) selectively stimulate Asp release, via D1 and CCKB receptor subtypes, respectively.	Cholecystokinin	18-33	cholecystokinin	Rattus norvegicus	35-38
9871461-6	1998	Dopamine (DA) and cholecystokinin (CCK) selectively stimulate Asp release, via D1 and CCKB receptor subtypes, respectively.	Cholecystokinin	18-33	cholecystokinin B receptor	Rattus norvegicus	75-99
9383204-6	1997	The hilar CGRP-positive neurons were negative for parvalbumin, calretinin, cholecystokinin and somatostatin, whereas most of them were immunoreactive for GluR2/3 (the AMPA-type glutamate receptor known to be expressed largely by principal cells).	Cholecystokinin	75-90	calcitonin-related polypeptide alpha	Rattus norvegicus	10-14
9277417-6	1997	These showed that plasma ALP activity increased significantly only after CCK-8 infusion.	Cholecystokinin	73-76	alkaline phosphatase, biomineralization associated	Canis lupus familiaris	25-28
9178925-8	1997	Carbachol, secretin, CCK-8 and prostaglandin E2 (PGE2) strongly stimulated mucin secretion, and gastrin I weakly did.	Cholecystokinin	21-24	solute carrier family 13 member 2	Rattus norvegicus	75-80
8596653-5	1995	After just 1 h, an increase in c-fos- and zif 268-like immunoreactivity is observed in the entire cortical hemisphere homolateral to the infarct, and is no longer detected after 6 h. An increase in cholecystokinin octapeptide-, substance P-, neuropeptide Y- and somatostatin-like immunoreactivity is observed in the entire cortical hemisphere homolateral to the infarct after three days, and is no longer detected after 30 days.	Cholecystokinin	198-213	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	31-36
8783263-6	1996	Parturition or systemic administration of cholecystokinin, that activate supraoptic and paraventricular neurons via ascending afferent pathways from the brainstem, both induced c-fos, but not the other genes, in the magnocellular nuclei.	Cholecystokinin	42-57	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	177-182
8601696-3	1996	Substance P-immunoreactive neurons, which made up approximately 20% of all neurons, exhibited heterogeneity by co-localization of immunoreactivities for dynorphin, for cholecystokinin, and for neurofilament triplet.	Cholecystokinin	168-183	tachykinin precursor 1	Homo sapiens	0-11
8626758-1	1996	The specificity and relative efficiency of cleavage of mono- and paired-basic residue processing sites by YAP3p was determined in vitro for a number of prohormone substrates: human ACTH1 39, bovine proinsulin, porcine cholecystokinin 33, cholecystokinin (CCK) 13-33, dynorphin A(1-11), dynorphin B(1-13), and amidorphin.	Cholecystokinin	218-233	Yap3p	Saccharomyces cerevisiae S288C	106-111
8848114-4	1995	Oxytocin antisense specifically (i) reduced the electrophysiological responses of putative oxytocin, but not vasopressin neurons, (ii) inhibited cholecystokinin-induced and electrically stimulated release of oxytocin from the neurohypophysis, and (iii) reversibly abolished cholecystokinin-induced expression of Fos within the supraoptic nucleus.	Cholecystokinin	145-160	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	312-315
8620842-4	1996	Characterization of colonic endocrine tumors in transgenic mice expressing simian virus 40 large T antigen under the control of the peptide YY gene 5" flanking region revealed tumor cells producing not only peptide YY and glucagon, but also neurotensin, cholecystokinin, substance P, serotonin, secretin, and gastrin.	Cholecystokinin	254-269	peptide YY	Mus musculus	132-142
8115034-9	1993	In the present study we report that the messenger RNA for the cholecystokininB receptor is present at very low levels in normal dorsal root ganglia of the rat, but axotomy causes a very marked increase in the number of sensory neurons of all sizes expressing cholecystokininB receptor messenger RNA, suggesting an increased sensitivity to cholecystokinin for many primary sensory neurons of different modalities after lesion.	Cholecystokinin	62-77	cholecystokinin B receptor	Rattus norvegicus	259-284
7525262-9	1994	However, when cells were contracted by the sulfated C-terminal octapeptide of cholecystokinin (10 nM), VIP, PTH-(1-34), and PTHrP(1-34) inhibited the sulfated C-terminal octapeptide of cholecystokinin-induced contraction in a concentration-dependent manner, whereas PTHrP-(1-16) and -(7-34) had no effect.	Cholecystokinin	78-93	vasoactive intestinal peptide	Homo sapiens	103-106
7525262-9	1994	However, when cells were contracted by the sulfated C-terminal octapeptide of cholecystokinin (10 nM), VIP, PTH-(1-34), and PTHrP(1-34) inhibited the sulfated C-terminal octapeptide of cholecystokinin-induced contraction in a concentration-dependent manner, whereas PTHrP-(1-16) and -(7-34) had no effect.	Cholecystokinin	78-93	parathyroid hormone	Homo sapiens	108-111
7525262-9	1994	However, when cells were contracted by the sulfated C-terminal octapeptide of cholecystokinin (10 nM), VIP, PTH-(1-34), and PTHrP(1-34) inhibited the sulfated C-terminal octapeptide of cholecystokinin-induced contraction in a concentration-dependent manner, whereas PTHrP-(1-16) and -(7-34) had no effect.	Cholecystokinin	78-93	parathyroid hormone like hormone	Homo sapiens	124-129
7525262-9	1994	However, when cells were contracted by the sulfated C-terminal octapeptide of cholecystokinin (10 nM), VIP, PTH-(1-34), and PTHrP(1-34) inhibited the sulfated C-terminal octapeptide of cholecystokinin-induced contraction in a concentration-dependent manner, whereas PTHrP-(1-16) and -(7-34) had no effect.	Cholecystokinin	78-93	parathyroid hormone like hormone	Homo sapiens	266-271
7816187-1	1994	The behavioural effects of two cholecystokinin analogues Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2 (JMV 236), a potent CCK agonist, and Boc-Tyr(SO3H)-Nle-Gly-DTrp-Nle-Asp-2-Phenylethylester (JMV 179), a CCK antagonist were studied.	Cholecystokinin	31-46	cholecystokinin	Rattus norvegicus	119-122
7942060-1	1994	The aim of this study was to investigate whether corticotropin-releasing factor influences the plasma levels of somatostatin, gastrin or cholecystokinin when administered intracerebroventricularly to rats, and if such an effect could be vagally mediated, and dependent on the animals feeding states.	Cholecystokinin	137-152	corticotropin releasing hormone	Rattus norvegicus	49-79
8226843-1	1993	It has been reported that the synthetic heptapeptide cholecystokinin (CCK) analogue JMV-180 evokes cytosolic Ca2+ signals in pancreatic acinar cells via mechanisms that do not include either the generation or action of inositol 1,4,5-trisphosphate (InsP3) (Saluja, A. K., Dawra, R. K., Lerch, M. M., and Steer, M. L. (1992) J. Biol.	Cholecystokinin	53-68	cholecystokinin	Mus musculus	70-73
7692048-1	1993	Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-2-phenylethyl ester (JMV180), an analog of the C-terminal octapeptide of cholecystokinin (CCK-8), shows interesting biological activities behaving as an agonist at the high-affinity CCK binding sites and as an antagonist at the low-affinity CCK binding sites in rat pancreatic acini.	Cholecystokinin	107-122	beta-secretase 1	Rattus norvegicus	30-35
8403531-12	1993	The PHI- and VIP-stimulated secretions were inhibited by a VIP antagonist, but not by a glucagon antagonist, SCH23390 (a dopamine D-1 antagonist), L-364718 (a cholecystokinin antagonist) or atropine.	Cholecystokinin	159-174	vasoactive intestinal peptide	Canis lupus familiaris	13-16
1397878-5	1992	These data indicate that endogenous cholecystokinin inhibits gastric acid secretion under basal conditions and gastrin release and gastric acid secretion during infusion of bombesin in humans and suggest that the augmented effect of loxiglumide on bombesin-stimulated gastric acid secretion may be explained largely by enhanced gastrin release.	Cholecystokinin	36-51	gastrin releasing peptide	Homo sapiens	173-181
8216742-3	1993	The results showed that (i) The antagonistic effect of CCK-8 on opioid-induced hypotension could be blocked by intrathecal (i. t.) administration of CCK-B antagonist L-365, 260 at nanogram doses, or by CCK-A antagonist devazepide at doses 20-40 times higher than L-365, 260, indicating that it was the CCK-B receptor which mediates the antiopioid effect.	Cholecystokinin	55-58	cholecystokinin B receptor	Homo sapiens	149-154
8216742-3	1993	The results showed that (i) The antagonistic effect of CCK-8 on opioid-induced hypotension could be blocked by intrathecal (i. t.) administration of CCK-B antagonist L-365, 260 at nanogram doses, or by CCK-A antagonist devazepide at doses 20-40 times higher than L-365, 260, indicating that it was the CCK-B receptor which mediates the antiopioid effect.	Cholecystokinin	55-58	cholecystokinin A receptor	Homo sapiens	202-207
8216742-3	1993	The results showed that (i) The antagonistic effect of CCK-8 on opioid-induced hypotension could be blocked by intrathecal (i. t.) administration of CCK-B antagonist L-365, 260 at nanogram doses, or by CCK-A antagonist devazepide at doses 20-40 times higher than L-365, 260, indicating that it was the CCK-B receptor which mediates the antiopioid effect.	Cholecystokinin	55-58	cholecystokinin B receptor	Homo sapiens	302-316
1397878-5	1992	These data indicate that endogenous cholecystokinin inhibits gastric acid secretion under basal conditions and gastrin release and gastric acid secretion during infusion of bombesin in humans and suggest that the augmented effect of loxiglumide on bombesin-stimulated gastric acid secretion may be explained largely by enhanced gastrin release.	Cholecystokinin	36-51	gastrin releasing peptide	Homo sapiens	248-256
1397878-5	1992	These data indicate that endogenous cholecystokinin inhibits gastric acid secretion under basal conditions and gastrin release and gastric acid secretion during infusion of bombesin in humans and suggest that the augmented effect of loxiglumide on bombesin-stimulated gastric acid secretion may be explained largely by enhanced gastrin release.	Cholecystokinin	36-51	gastrin	Homo sapiens	328-335
1340058-3	1992	Using this assay, high doses of cholecystokinin or carbachol were found to stimulate the intracellular conversion of at least three zymogens (procarboxypeptidase A1, procarboxypeptidase B, and chymotrypsinogen 2) to their active forms.	Cholecystokinin	32-47	carboxypeptidase B1	Homo sapiens	166-187
1766000-0	1991	Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors.	Cholecystokinin	0-15	cholecystokinin A receptor	Homo sapiens	106-111
1378274-3	1992	IC50 of CP 96,345 for binding of [125I]-BH-SP and for SP-induced (3 x 10(-9) M) rise of [Ca2+]i were about 10(-9) M. CP-96,345 neither affected binding of [125I]-labelled Bolton-Hunter cholecystokinin octapeptide ([125I]-BH-CCK-8) nor the [Ca2+]i responses to CCK-8, carbamylcholine or bombesin.	Cholecystokinin	185-200	tachykinin precursor 1	Homo sapiens	54-56
1802707-10	1991	Finally, Northern blots with a cDNA of rat cathepsin B showed that the concentration of cathepsin B mRNA in total pancreatic RNA increased following in vivo stimulation of the exocrine pancreatic cells with optimal doses of cerulein, a cholecystokinin analogue.	Cholecystokinin	236-251	cathepsin B	Rattus norvegicus	88-99
1932479-0	1991	Inhibition of gastrin- and histamine-stimulated gastric acid secretion by gastrin and cholecystokinin antagonists in the rat.	Cholecystokinin	86-101	gastrin	Rattus norvegicus	14-21
1720905-3	1991	In the presence of a submaximal dose of PACAP 38 (1 nM), amylase release stimulated by an agonist working via the elevation of intracellular cyclic AMP (VIP, dibutyryl cAMP) was additionally responded, but the amylase release stimulated by an agonist via the elevation of cytosolic free calcium (carbachol, cholecystokinin) was potentiated synergistically.	Cholecystokinin	307-322	vasoactive intestinal peptide	Rattus norvegicus	153-156
1901391-6	1991	Passive immunoneutralization studies with anti-VIP antisera suggest that endogenous VIP acts at multiple loci in the hypothalamic-pituitary axis to regulate PRL secretion, interacting possibly with other regulators of PRL secretion such as estrogen, serotonin, cholecystokinin, prostaglandins, galanin and oxytocin.	Cholecystokinin	261-276	vasoactive intestinal peptide	Homo sapiens	84-87
34942530-3	2022	Cholecystokinin (CCK) is a gut-brain neuropeptide and involved in morphine dependence.	Cholecystokinin	0-15	cholecystokinin	Mus musculus	17-20
2204682-4	1990	The selective presence of PST in the neurons of the CNS raises the issue as to the role of this enzyme in sulfating neurotransmitters because PST has been shown to be capable of conjugating a variety of neurotransmitters including the catecholamines as well as the tyrosine moiety of a number of small peptides such as enkephalin and cholecystokinin.	Cholecystokinin	334-349	sulfotransferase family 1A member 1	Homo sapiens	26-29
2204682-4	1990	The selective presence of PST in the neurons of the CNS raises the issue as to the role of this enzyme in sulfating neurotransmitters because PST has been shown to be capable of conjugating a variety of neurotransmitters including the catecholamines as well as the tyrosine moiety of a number of small peptides such as enkephalin and cholecystokinin.	Cholecystokinin	334-349	sulfotransferase family 1A member 1	Homo sapiens	142-145
33794246-4	2021	Cholecystokinin (CCK) is the most abundant neuropeptide in the mammal brain, where it activates two receptors, CCK1 and CCK2.	Cholecystokinin	0-15	cholecystokinin	Homo sapiens	17-20
33794246-4	2021	Cholecystokinin (CCK) is the most abundant neuropeptide in the mammal brain, where it activates two receptors, CCK1 and CCK2.	Cholecystokinin	0-15	C-C motif chemokine ligand 28	Homo sapiens	111-115
34779255-1	2022	Cholecystokinin (CCK) increases core body temperature via CCK2 receptors when administered intracerebroventricularly (icv).	Cholecystokinin	0-15	cholecystokinin	Rattus norvegicus	17-20
34844019-0	2022	Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.	Cholecystokinin	83-98	glucagon like peptide 1 receptor	Homo sapiens	34-48
34740874-5	2022	Cholecystokinin (CCK) is a peptide hormone typically produced in the gut after food intake, with positive effects on obesity and glucose metabolism in mouse models and human subjects.	Cholecystokinin	0-15	cholecystokinin	Mus musculus	17-20
34719328-10	2021	Cognitive performance was validated by Morris Water Maze (MWM), and gene expression by RT-qPCR, Cholecystokinin (CCK), Tachykinin precursor 1 (TAC1), Calbindin 1 (CALB1) were downregulated in the hippocampus.	Cholecystokinin	96-111	cholecystokinin	Homo sapiens	113-116
34626852-10	2021	Sequencing approaches combining ex-vivo and in-vivo experiments revealed that FFAR3 signaling cross-talks with cholecystokinin (CCK) and leptin receptor pathways to alter food intake.	Cholecystokinin	111-126	free fatty acid receptor 3	Mus musculus	78-83
34626852-10	2021	Sequencing approaches combining ex-vivo and in-vivo experiments revealed that FFAR3 signaling cross-talks with cholecystokinin (CCK) and leptin receptor pathways to alter food intake.	Cholecystokinin	111-126	cholecystokinin	Mus musculus	128-131
34792009-6	2022	The effect of CCNE1 on LUAD cells proliferation and apoptosis was evaluated through Cell Counting Kit-8 (CCK-8), colony formation, and Annexin V/propidium iodide (AV-PI) assays, respectively.	Cholecystokinin	105-108	cyclin E1	Mus musculus	14-19
34510848-12	2021	The PI3K and HIF-1alpha inhibitors also abolished the effects of CCK-8 preconditioning on HIF-1alpha, p-Akt and p-GSK-3beta/GSK-3beta.	Cholecystokinin	65-68	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	13-23
34510848-12	2021	The PI3K and HIF-1alpha inhibitors also abolished the effects of CCK-8 preconditioning on HIF-1alpha, p-Akt and p-GSK-3beta/GSK-3beta.	Cholecystokinin	65-68	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	90-100
34510848-12	2021	The PI3K and HIF-1alpha inhibitors also abolished the effects of CCK-8 preconditioning on HIF-1alpha, p-Akt and p-GSK-3beta/GSK-3beta.	Cholecystokinin	65-68	AKT serine/threonine kinase 1	Rattus norvegicus	104-107
34510848-12	2021	The PI3K and HIF-1alpha inhibitors also abolished the effects of CCK-8 preconditioning on HIF-1alpha, p-Akt and p-GSK-3beta/GSK-3beta.	Cholecystokinin	65-68	glycogen synthase kinase 3 alpha	Rattus norvegicus	114-123
34510848-12	2021	The PI3K and HIF-1alpha inhibitors also abolished the effects of CCK-8 preconditioning on HIF-1alpha, p-Akt and p-GSK-3beta/GSK-3beta.	Cholecystokinin	65-68	glycogen synthase kinase 3 alpha	Rattus norvegicus	124-133
34423157-1	2021	Background: Biliary dyskinesia generally refers to a hypofunctioning gallbladder with an ejection fraction (EF) of <35% on hepatobiliary iminodiacetic acid scan with cholecystokinin stimulation (CCK-HIDA testing).	Cholecystokinin	166-181	cholecystokinin	Homo sapiens	195-198
34287873-0	2021	Evidence that Increased Cholecystokinin (CCK) in the Periaqueductal Gray (PAG) Facilitates Changes in Resident-Intruder Social Interactions Triggered by Peripheral Nerve Injury.	Cholecystokinin	24-39	cholecystokinin	Rattus norvegicus	41-44
34655712-1	2021	Cholecystokinin (CCK) is an appetite-suppressing hormone that acts in the dorsomedial hypothalamus (DMH) in adult rats to suppress food intake.	Cholecystokinin	0-15	cholecystokinin	Rattus norvegicus	17-20
34639136-7	2021	CONCLUSIONS: alpha-CD elicits its anti-hyperglycemic effect after glucose loading by inducing lecithin inclusion in the gut lumen and activating SREBP2, which is known to induce cholecystokinin secretion to suppress hepatic glucose production via a gut/brain/liver axis.	Cholecystokinin	178-193	adrenocortical dysplasia	Mus musculus	13-21
34639136-7	2021	CONCLUSIONS: alpha-CD elicits its anti-hyperglycemic effect after glucose loading by inducing lecithin inclusion in the gut lumen and activating SREBP2, which is known to induce cholecystokinin secretion to suppress hepatic glucose production via a gut/brain/liver axis.	Cholecystokinin	178-193	sterol regulatory element binding factor 2	Mus musculus	145-151
34398892-4	2021	We found that feeding increases the expression of the cholecystokinin-like peptide, sulfakinin (SK), and the activity of a set of SK-expressing neurons.	Cholecystokinin	54-69	Drosulfakinin	Drosophila melanogaster	84-94
34398892-4	2021	We found that feeding increases the expression of the cholecystokinin-like peptide, sulfakinin (SK), and the activity of a set of SK-expressing neurons.	Cholecystokinin	54-69	Drosulfakinin	Drosophila melanogaster	96-98
34422806-5	2021	The in vitro effects of TMEM220-AS1 on HCC cells were determined using Cell Counting Kit-8 (CCK-8), 5-ethynyl-2"-deoxyuridine (EdU), flow cytometry, and Transwell assays in HCC cells.	Cholecystokinin	92-95	transmembrane protein 220	Homo sapiens	24-31
34349610-5	2021	Cerulein, a cholecystokinin analog, induces calcium (Ca2+) overload, oxidative stress, and IL-6 expression in pancreatic acinar cells, which are hallmarks of acute pancreatitis.	Cholecystokinin	12-27	interleukin 6	Homo sapiens	91-95
34239417-10	2021	We found that two gut hormones, leptin and cholecystokinin, differentially modulate PPG neurons.	Cholecystokinin	43-58	glucagon	Homo sapiens	84-87
34371941-7	2021	IGFBP6 correlated positively with apelin, cholecystokinin, glucagone-like peptide-1, and leptin receptor.	Cholecystokinin	42-57	insulin like growth factor binding protein 6	Homo sapiens	0-6
34239417-11	2021	Cholecystokinin reduces or increases spike frequency, suggesting a heterogeneous signaling pathway in different PPG neurons, while leptin does not affect PPG neuronal firing.	Cholecystokinin	0-15	glucagon	Homo sapiens	112-115
34086670-3	2021	Here, we used cryo-electron microscopy (cryo-EM) to determine structures of the cholecystokinin (CCK) type 1 receptor (CCK1R) bound to the CCK peptide agonist, CCK-8 and 2 distinct transducer proteins, its primary transducer Gq, and the more weakly coupled Gs.	Cholecystokinin	80-95	cholecystokinin A receptor	Homo sapiens	119-124
34086670-3	2021	Here, we used cryo-electron microscopy (cryo-EM) to determine structures of the cholecystokinin (CCK) type 1 receptor (CCK1R) bound to the CCK peptide agonist, CCK-8 and 2 distinct transducer proteins, its primary transducer Gq, and the more weakly coupled Gs.	Cholecystokinin	80-95	cholecystokinin	Homo sapiens	139-142
35338913-5	2022	Moreover, knockdown of circ_0043533 in OGC lines COV434 and KGN, respectively, the cell viability, proliferation, apoptosis, and cycle-related markers of insulin-triggered OGCs were examined by CCK-8, EdU staining, flow cytometry, and western blot assays, respectively.	Cholecystokinin	194-197	insulin	Homo sapiens	154-161